The renal bone diseases in children treated with dialysis.

[1]  G. Segre,et al.  Calcium-regulated parathyroid hormone secretion in adynamic renal osteodystrophy. , 1995, Kidney International.

[2]  W. Goodman,et al.  Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. , 1995, Kidney international.

[3]  Y. Tsukamoto,et al.  Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  A. Arnold,et al.  Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. , 1995, The Journal of clinical investigation.

[5]  E. Brown,et al.  Sensing of extracellular Ca2+ by parathyroid and kidney cells: cloning and characterization of an extracellular Ca(2+)-sensing receptor. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  E. Ritz,et al.  Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  E. Brown,et al.  Calcium receptor messenger ribonucleic acid levels in the parathyroid glands and kidney of vitamin D-deficient rats are not regulated by plasma calcium or 1,25-dihydroxyvitamin D3. , 1995, Endocrinology.

[8]  K. Kurokawa,et al.  Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. , 1995, Nephron.

[9]  P. Messa,et al.  Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. , 1994, Kidney international.

[10]  G. Segre,et al.  Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. , 1994, The American journal of physiology.

[11]  E. Bonucci,et al.  Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. , 1994, Kidney international.

[12]  E. Ogata,et al.  Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. , 1994, Kidney international.

[13]  G. Segre,et al.  Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. , 1994, Kidney international.

[14]  J. Heaf,et al.  Osteocalcin: a non-invasive index of metabolic bone disease in patients treated by CAPD. , 1994, Kidney international.

[15]  H. Malluche,et al.  Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. , 1994, Kidney international.

[16]  B. Lacour,et al.  The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. , 1994, Kidney international.

[17]  E. Bonucci,et al.  Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study. , 1994, Mineral and electrolyte metabolism.

[18]  R. Whitehouse,et al.  Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. , 1994, American journal of nephrology.

[19]  S. Pflanz,et al.  Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  G. Segre,et al.  Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. , 1994, Kidney international.

[21]  E. Ogata,et al.  Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. , 1994, Nephron.

[22]  A. Torres,et al.  Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  E. Ritz,et al.  Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. , 1993, Kidney international.

[24]  D. Sherrard,et al.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. , 1993, Kidney international.

[25]  K. Kurokawa,et al.  Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. , 1993, The Journal of clinical investigation.

[26]  W. Goodman,et al.  Recent advances in the management of renal osteodystrophy in children. , 1993, Current opinion in nephrology and hypertension.

[27]  G. Segre,et al.  Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. , 1993, Journal of the American Society of Nephrology : JASN.

[28]  J. Gornbein,et al.  Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. , 1993, The Journal of clinical endocrinology and metabolism.

[29]  A. Fine,et al.  Elevation of serum phosphate affects parathyroid hormone levels in only 50% of hemodialysis patients, which is unrelated to changes in serum calcium. , 1993, Journal of the American Society of Nephrology : JASN.

[30]  R. Tabah,et al.  Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. , 1993, Clinical nephrology.

[31]  Y. Pei,et al.  The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.

[32]  M. Brandi,et al.  Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. , 1993, The Journal of clinical endocrinology and metabolism.

[33]  J. Delmez,et al.  Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. , 1992, Kidney international. Supplement.

[34]  M. Monier‐Faugere,et al.  Risk of adynamic bone disease in dialyzed patients. , 1992, Kidney international. Supplement.

[35]  L. Quarles,et al.  Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. , 1992, The Journal of clinical endocrinology and metabolism.

[36]  B. Boudailliez,et al.  Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment? , 1992, Bone.

[37]  N. Vega,et al.  Low turnover bone disease is the more common form of bone disease in CAPD patients. , 1992, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[38]  B. Boudailliez,et al.  Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. , 1991, The Journal of clinical endocrinology and metabolism.

[39]  W. Goodman,et al.  Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. , 1991 .

[40]  Alex J. Brown,et al.  The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. , 1989, Contributions to nephrology.

[41]  K. Schaefer,et al.  The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  W. Goodman,et al.  Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy. , 1991, Contributions to nephrology.

[43]  R. Dunlay,et al.  A comparison of parathyroid-gland function in haemodialysis patients with different forms of renal osteodystrophy. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  J. Silver,et al.  Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. , 1990, The Journal of clinical investigation.

[45]  A. Dusso,et al.  Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. , 1990, The American journal of physiology.

[46]  P. Marie,et al.  Relationships between histomorphometric features of bone formation and bone cell characteristics in vitro in renal osteodystrophy. , 1989, The Journal of clinical endocrinology and metabolism.

[47]  B. Molitoris,et al.  Citrate: a major factor in the toxicity of orally administered aluminum compounds. , 1989, Kidney international.

[48]  L. Schiller,et al.  Calcium acetate, an effective phosphorus binder in patients with renal failure. , 1989, Kidney international.

[49]  J. Delmez,et al.  Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. , 1989, The Journal of clinical investigation.

[50]  E. Ritz,et al.  1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. , 1989, Kidney international.

[51]  W. Goodman,et al.  Features of renal osteodystrophy in pediatric patients receiving regular peritoneal dialysis. , 1989, Seminars in nephrology.

[52]  L. Schiller,et al.  Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. , 1989, The Journal of clinical investigation.

[53]  W. Goodman,et al.  Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. , 1988, Kidney international.

[54]  C. Cann,et al.  Quantitative CT for determination of bone mineral density: a review. , 1988, Radiology.

[55]  E. Slatopolsky,et al.  Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. , 1987, Kidney international.

[56]  J. Delmez,et al.  The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. , 1987, Kidney international.

[57]  J. Russell,et al.  Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. , 1986, Endocrinology.

[58]  D. Sherrard,et al.  Aluminum‐associated bone disease in chronic renal failure: High prevalence in a long‐term dialysis population , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  S. Ott,et al.  Parathyroid hormone in aluminum bone disease: a comparison of parathyroid hormone assays. , 1986, Kidney international. Supplement.

[60]  H. Harter,et al.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. , 1984, The Journal of clinical investigation.

[61]  A. Cheung,et al.  Determinants of serum 1,25(OH)2D levels in renal disease. , 1983, Kidney international.

[62]  E. Brown,et al.  Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. , 1983, The Journal of clinical endocrinology and metabolism.

[63]  R. Morris,et al.  Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. , 1982, Kidney international.

[64]  E. Brown,et al.  Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. , 1982, The Journal of clinical endocrinology and metabolism.

[65]  S. Pedersen,et al.  DIALYSIS ENCEPHALOPATHY IN A NON‐DIALYSED URAEMIC BOY TREATED WITH ALUMINIUM HYDROXIDE ORALLY , 1980, Acta paediatrica Scandinavica.

[66]  A. Pierides,et al.  Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. , 1980, Kidney international.

[67]  M. Haussler,et al.  Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. , 1977, The Journal of clinical endocrinology and metabolism.

[68]  W. Suki,et al.  Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. , 1976, Archives of internal medicine.

[69]  A. Alfrey,et al.  Extraosseous calcification. Evidence for abnormal pyrophosphate metabolism in uremia. , 1976, The Journal of clinical investigation.

[70]  J. H. Kaye,et al.  Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism. , 1975, The Journal of clinical endocrinology and metabolism.

[71]  J. Wergedal,et al.  Quantitative histological studies on the pathogenesis of uremic bone disease. , 1974, The Journal of clinical endocrinology and metabolism.

[72]  S. Genuth,et al.  Osteomalacia accompanying chronic anticonvulsant therapy. , 1972, The Journal of clinical endocrinology and metabolism.

[73]  E. Kaplan,et al.  The role of phosphate in the secretion of parathyroid hormone in man. , 1970, The Journal of clinical investigation.